Bookmarking this. I will come back when I have something worth adding.
Everything in post #9 holds. The case it does not cover is the one I have.
The gastrointestinal tolerability profile of the oral formulation is broadly similar in character to the injectable, which supports the effects being systemic rather than local irritation.
The strength of my opinion here exceeds the strength of my evidence.
Timing consistency matters more for oral dosing than for weekly injection, because absorption depends on the state of the stomach and the state of the stomach varies through the day.
Appreciated. The plain phrasing does more work here than a longer post would.
SNAC is the sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, an absorption enhancer that transiently raises local pH in the stomach and promotes gastric mucosal absorption. Without it, oral bioavailability of semaglutide would be too low for clinically useful dosing.
If this contradicts something upthread, the upthread version may well be the better one.
Read the full topic (49 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — setting out what I have, and where I think it stops being reliable. Posting a small dataset on PIONEER 6 cardiovascular…
|
+25 | 29 | 22k | 1d |
|
Oral semaglutide bioavailability and its variability between people — a second dataset
Oral semaglutide bioavailability and its variability between people — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Oral semaglutide…
|
+141 | 154 | 47k | 19mo |
|
Why oral semaglutide needs an absorption enhancer at all
Why oral semaglutide needs an absorption enhancer at all I have a specific reason for asking rather than idle curiosity, and the context is below. Reading back through what has been written here about oral…
|
+59 | 65 | 61k | 7mo |
|
Why oral semaglutide needs an absorption enhancer at all — one year on
Why oral semaglutide needs an absorption enhancer at all — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. Reading back through what has been written here…
|
+11 | 15 | 17k | 24d |
|
Oral versus injectable exposure: comparing apples to a different fruit
Oral versus injectable exposure: comparing apples to a different fruit — setting out what I have, and where I think it stops being reliable. Something about oral versus injectable exposure does not reconcile…
|
+19 | 23 | 332 | 8mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists
Posting this under the heading it deserves: Nausea profile of amylin analogues compared with GLP-1 agonists Everything below is what sits behind that. Nausea profile of amylin analogues — I have the…
|
+48 | 53 | 31k | 13mo |
|
Why oral semaglutide needs an absorption enhancer at all — one year on
Why oral semaglutide needs an absorption enhancer at all — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. Reading back through what has been written here…
|
+11 | 15 | 17k | 24d |
|
Food effects on oral incretin absorption: what is documented
On the subject in the title: Food effects on oral incretin absorption: what is documented Working notes rather than a conclusion. Food effects on oral incretin, from the point of view of someone who has read…
|
2 | 4.4k | 12mo | |
|
Primary endpoint hierarchies and why order matters — one year on
On the subject in the title: Primary endpoint hierarchies and why order matters — one year on Working notes rather than a conclusion. A follow-up question about Primary endpoint hierarchies that I did not…
|
+56 | 61 | 37k | 11h |
|
Oral versus injectable exposure: comparing apples to a different fruit
Oral versus injectable exposure: comparing apples to a different fruit — setting out what I have, and where I think it stops being reliable. Something about oral versus injectable exposure does not reconcile…
|
+19 | 23 | 332 | 8mo |